Language selection

Search

Patent 2269910 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent Application: (11) CA 2269910
(54) English Title: NEW PROCESS FOR THE PREPARATION OF MORPHINANS
(54) French Title: NOUVEAU PROCEDE DE PREPARATION DE MORPHINANES
Status: Dead
Bibliographic Data
(51) International Patent Classification (IPC):
  • C07D 489/09 (2006.01)
  • C07D 491/18 (2006.01)
(72) Inventors :
  • WEI, ZHONG-YONG (Canada)
  • SCHMIDHAMMER, HELMUT (Austria)
  • SCHWARZ, PETER (Austria)
(73) Owners :
  • ASTRA AKTIEBOLAG (Sweden)
(71) Applicants :
  • ASTRA AKTIEBOLAG (Sweden)
(74) Agent: FETHERSTONHAUGH & CO.
(74) Associate agent:
(45) Issued:
(86) PCT Filing Date: 1996-11-19
(87) Open to Public Inspection: 1998-05-28
Availability of licence: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): Yes
(86) PCT Filing Number: PCT/SE1996/001497
(87) International Publication Number: WO1998/022467
(85) National Entry: 1999-04-26

(30) Application Priority Data: None

Abstracts

English Abstract




A process for the preparation of 14-alkoxyindolomorphinans and 14-
alkoxybenzofuranomorphinans is disclosed. The process facilitates the
preparation of a large variety of 14-alkoxy substituted indolomorphinans and
benzofuranomorphinans in which a 3-hydroxy substituent is present.


French Abstract

L'invention a trait à un procédé de préparation de 14-alcoxyindolomorphinanes et de 14-alcoxybenzofuranomorphinanes. Ce procédé rend plus aisée la préparation d'une grande variété d'indolomorphinanes et de benzofuranomorphinanes à substitution 14-alcoxy dans lesquelles est présent un substituant 3-hydroxy.

Claims

Note: Claims are shown in the official language in which they were submitted.





27


Claims


1. A process for the preparation of a compound of the formula (I)

Image

wherein

R1 represents allyl, cyclopropylmethyl or methyl;

R2 represents C1-C6 alkoxy, C1-C6 alkenyloxy, C7-C16 arylalkyloxy wherein aryl
is
C6-C10 aryl and alkyloxy is C1-C6 alkyloxy, C7-C16 arylalkenyloxy wherein aryl
is C6-C10
aryl and alkenyloxy is C1-C6 alkenyloxy, C1-C6 alkanoyloxy, C7-C16
arylalkanoyloxy
wherein aryl is C6-C10 aryl and alkanoyloxy is C1-C6 alkanoyloxy;

R3 represents hydroxy, C1-C6 alkoxy, C7-C16 arylalkyloxy wherein aryl is C6-
C10 aryl and
alkyloxy is C1-C6 alkyloxy, C1-C6 alkenyloxy, C1-C6 alkanoyloxy, C7-C10
arylalkanoyloxy
wherein the aryl is C6-C10 aryl and the alkanoyloxy is C1-C6 alkanoyloxy, C2-
C10
alkyloxyalkoxy wherein alkyloxy is C1-C4 alkyloxy and alkoxy is C1-C6 alkoxy;
and
X represents O, NH or NR4 wherein R4 is C1-C6 alkoxy, C1-C6 alkenyloxy, C7-C16
arylalkyloxy wherein aryl is C6-C10 aryl and alkyloxy is C1-C6 alkyloxy, C1-
C16
arylalkenyloxy wherein the aryl is C6-C10 aryl and alkenyloxy is C1-C6
alkenyloxy, C7-C16
alkanoyloxy, C7-C16 arylalkanoyloxy wherein aryl is C6-C10 aryl and
alkanoyoloxy is
C1-C6 alkanoyloxy;




28


comprising the following steps:
(i) naloxone (II), naltrexone (III) or oxymorphone (IIIa) of the formula

Image

(II): R = allyl
(III): R = cyclopropylmethyl
(IIIa): R = methyl


is reacted with phenylhydrazine hydrochloride in the presence of acid, giving
naloxindole
(NLI), naltrindole (NTI) or oxymorphindole (OMI), of the formula

Image

NLl: R = allyl, X = NH
NTI: R = cyclopropylmethyl, X = NH
OMI: R = methyl, X = NH

or

naloxone (II), naltrexone (III) or oxymorphone (IIIa) is reacted with O-phenyl-
hydroxyl
amine hydrochloride in the presence of acid, giving the benzofurane
derivatives NLB,
naltriben (NTB) or OMB of the formula




29


Image

NLB: R = allyl, X = O
NTB: R = cyclopropylmethyl, X = O
OMB: R = methyl, X = O

(ii) the 3-hydroxy group is protected by alkylation with benzyl bromide,
methoxymethyl
bromide, ethoxymethyl bromide, trityl chloride, or a silylating agent, in the
presence of a
solvent and a base, giving a compound of the formula (IV)

Image

wherein
R1 is allyl, cyclopropylmethyl or methyl;

R2 is benzyl, methoxymethyl, ethoxymethyl, trityl or silyl; and

X is NH, O, N-benzyl, N-methoxymethyl, N-ethoxymethyl, N-trityl or N-silyl;

(iii) the compound of the formula (IV) is treated with C1-C2 dialkyl sulfates,
C1-C6 alkyl
halides, C1-C6 alkenyl halides, C7-C16 aralkyl halides wherein the aryl is C6-
C10 aryl and
the alkyl is C1-C6 alkyl, C7-C16 arylalkenyl halides wherein the aryl is C6-
C10 aryl and the
alkenyl is C2-C6 alkenyl, C2-C6 alkanoyl halides, or C7-C16 arylalkanoyl
halides wherein
the aryl is C6-C10 aryl and the alkanoyl is C2-C6 alkanoyl, in a solvent,
preferably N,




30


N-dimethyl formamide or tetrahydrofurane, using a base, giving a compound of
the formula
(V)

Image

wherein
R1 is allyl, cyclopropylmethyl or methyl;
R2 is benzyl, methoxymethyl, ethoxymethyl, trityl or silyl; and
R3 is C1-C6 alkyl, C1-C6 alkenyl; C7-C16 arylalkyl wherein the aryl is C6-C10
aryl and the
alkyl is C1-C6 alkyl; C7-C16 arylalkenyl wherein the aryl C6-C10 aryl and the
alkenyl is
C1-C6 alkenyl; C1-C6 alkanoyl, C7-C16 arylalkanoyl wherein the aryl is C6-C10
aryl and the
alkyl is C1-C6 alkyl;
X is as defined in the formula (IV) above; and
optionally the following step (iv) whereby
(iv) the compound of the formula (V) wherein X is as defined in formula (IV)
above, is
hydrolized in diluted acids, optionally in the presence of a solvent, giving a
compound of the
formula (VI)




31


Image


wherein R1, and R2 are as defined above in formula (V), and X is NH, O or N-
benzyl; and
(v) the compound of the formula (VI) is alkylated or acylated, giving a
compound of the
formula (I).
2. A process according to claim 1, wherein
R1 is allyl or cyclopropylmethyl;
R2 is C1-C6 alkoxy, C1-C6 alkenyloxy, C7-C16 arylalkyloxy, C7-C16
arylalkenyloxy;
R3 is hydroxy, C1-C6 alkoxy, C1-C6 alkanoyloxy.

3. A process according to claim 1, whereby the acid used in step (i) is
selected from
methanesulfonic acid, sulfuric acid and hydrochloric acid.

4. A process according to claim 1, whereby the protection of the 3-hydroxy
group in step
(ii) is performed by alkylation with dimethyl isobutyl-silyl chloride,
trimethylsilyl chloride)
triethylsilyl chloride, t-butyldimethylsilyl chloride and tri-i-propylsilyl
chloride.

5. A process according to claim 1, whereby the solvent in step (ii) is
selected from N,
N-dimethylformamide, dichloromethane and tetrahydrofurane.

6. A process according to claim 1, whereby the base in step {ii) is selected
from potassium
carbonate, potassium hydroxide, sodium hydride, sodium amide and diisopropyl
ethylamine.




32

7. A process according to claim 1, whereby the solvent in step (iii) is
selected from N,
N-dimethylformamide and tetrahydrofurane.
8. A process according to claim 1, whereby the strong base in step (iii) is
selected from
sodium hydride, potassium hydride and sodium amide.
9. A process according to claim 1, whereby the diluted acid in step (iv) is
hydrochloric
acid or sulfuric acid.
10. A process according to claim 1, whereby step (iv) is performed in the
presence of a
solvent.
11. A process according to claim 10, whereby the solvent is an alcohol.
12. A process according to claim 11, whereby the solvent is selected from
methanol,
ethanol and propanol.




1

CLAIMS:

14. A compound according to formula (IV)

Image

wherein
R1 is allyl, cyclopropylmethyl or methyl;
R2 is benzyl, methoxymethyl, ethoxymethyl, trityl, silyl, dimethyl isobutyl
silyl,
trimethylsilyl, triethylsilyl, t-butyldimethylsilyl or tri-i-propylsilyl; and


X is NH, O, N-benzyl, N-methoxymethyl, N-ethoxymethyl, N-trityl, N-silyl,
dimethyl
isobutyl silyl, trimethylsilyl, triethylsilyl, t-butyldimethylsilyl or tri-i-
propylsilyl;


and with the proviso that:

(i) when R1 is cyclopropylmethyl and R2 is methoxymethyl, X is not O or
N-methoxymethyl.




2

15. A compound according to the formula (V)

Image

wherein

R1 is allyl or cyclopropylmethyl;
R2 is benzyl, methoxymethyl, ethoxymethyl, trityl or silyl; and
R3 is C1-C6 alkyl, C7-C6 alkenyl; C7-C16 arylalkyl wherein the aryl is C6-C10
aryl and the
alkyl is C1-C6 alkyl; C1-C16 arylalkenyl wherein the aryl C6-C10 aryl and the
alkenyl is
C1-C6 alkenyl; C1-C6 alkanoyl, C7-C16 arylalkanoyl wherein the aryl is C6-C10
aryl and
the alkyl is C1-C6 alkyl;

X is NH, O, N-benzyl, N-methoxymethyl, N-ethoxymethyl, N-trityl, N-silyl,
dimethyl
isobutyl silyl, trimethylsilyl, triethylsilyl, t-butyldimethylsilyl or tri-i-
propylsilyl; and

with the proviso that:

(j) when R1 is cyclopropylmethyl, R2 is methoxymethyl and R3 is methyl, X is
not O.

Description

Note: Descriptions are shown in the official language in which they were submitted.



CA 02269910 1999-04-26
WO 98/22467 PCT/SE96/01497 -
1
NEW PROCESS FOR THE PREPARATION OF MORPHINANS
Field of the invention
s
The present invention is directed to a new process for the preparation of
14-alkoxyindolomorphinans and 14-alkoxybenzofuranomorphinans.
Background of the invention
io
Opioid antagonists have been indispensable as tools in opioid research. For
example, the
chief criterion for the classification of an agonist effect as being opioid
receptor mediated is
the ability of known opioid antagonists naioxone or naltrexone to reversibly
antagonize this
effect in a competitive fashion. The usefulness of naloxone and naltrexone for
this purpose
is stems from the fact that they are universal opioid antagonists; that is,
they are capable of
antagonizing the agonist effects mediated by multiple opioid receptor types.
In addition to their uses as pharmacological tools, selective, non-peptide
opioid antagonists
have been described as having potential clinical applications in the treatment
of a variety of
zo disorders where endogenous opioids play a modulatory role. These include
for instance
disorders of food intake, shock, constipation, mental disorders, CNS injury,
alcoholism, and
immune function (P.S. Portoghese at al., J. Med. Chem., Vol. 34: 1757-1762,
l991).
Non-peptide, competitive, S-selective opioid antagonists have been found to
have
zs immunosuppressive potency and less toxicity than the presently used
immunosuppressive
compound cyclosporin (EP 45b 833; EP 485 636; EP 614 898; K. Arakawa et al.,
Transplantation, Vol. 53: 951-953, l992; K. Arakawa et al., Transplant Proc.,
Vol. 24:
696-697, 1992; K. Arakawa et al., Transplant Proc., Vol. 25: 738-740, 1993).
Such
immunosuppressive agents can be used after organ transplantation to suppress
the rejection
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98I22467 PCT/SE96/01497 _
2
of the foreign organ and also in the treatment of autoimmune diseases (e.g.
rheumatoid
arthritis).
In US 5 223 507 and US 5 225 417 the synthesis of 14-O-substituted
indolomorphinans and
s benzofuranomorphinans have been disclosed. According to the process used for
preparing
the compounds claimed and disclosed in US 5 223 507, only a 3,14-dimethoxy
substituted
benzofuranomorphinan was prepared. According to the process used for preparing
compounds claimed and disclosed in US 5 225 417, two 14-O-alkyl substituted
benzofuranomorphinans have been prepared. According to the methods used for
preparing
~ o the compounds of both the two mentioned prior art documents, the 3-hydroxy
group was
protected by a methyl group which is not easily removed without having a loss
in yield.
According to the processes known from the prior art, the variations of the
substituents at
the oxygen in position 14 are very much limited when a 3-hydroxy group is
supposed to be
~ s present in the molecule. It is for instance not possible to prepare
compounds with a
substituent at the oxygen in 14-position, as this position is labile to the
conditions used for
the cleavage of the 3-methoxy group.
Thus, the object of the present invention was to find a new process which
would facilitate
2o the preparation of 14-O-substituted indolomorphinans and
benzofuranomorphinans.
The present patent application discloses a process whereby naloxone,
naltrexone or
oxymorphone is used as the starting material, whereby the 14-alkoxy group is
introduced
after the protection of the oxygen in 3-position with an easily removable
protecting group,
is preferably benzyl, methoxymethyl, ethoxymethyl, trityl or silyl, thereby
providing a process
enabling the synthesis of compounds involving 14-O-substitution.
SUBSTITUTE SHEET (RULE 26)



CA 02269910 1999-04-26
WO 98I22467 PCT/SE96/01497 _
3
Outline of the invention
The present invention is directed to a new process for the preparation of
compounds of the
general formula (I)
s
wherein
R1 represents allyl, cyclopropylmethyl or methyl;
io
R2 represents C 1-C6 alkoxy, C 1-C6 alkenyloxy, C~-C 16 arylalkyloxy wherein
aryl is
C6-C ~ p aryl and alkyloxy is C ~ -C6 alkyloxy, C~-C I 6 arylalkenyloxy
wherein aryl is C6-C 1 p
aryl and alkenyloxy is C 1-C6 alkenyloxy, C 1-C6 alkanoyloxy, C~-C 16
arylalkanoyloxy
wherein aryl is C6-Clp aryl and alkanoyloxy is C1-C6 alkanoyloxy;
R3 represents hydroxy, C 1-C6 alkoxy) C~-C I 6 arylalkyloxy wherein aryl is C6-
C ~ p aryl and
alkyloxy is C ~ -C6 alkyloxy, C ~ -C6 alkenyloxy) C I -C6 alkanoyloxy, C~-C 16
arylalkanoyloxy
wherein the aryl is C6-C 1 p aryl and the alkanoyloxy is C 1-C6 alkanoyloxy,
C2-C ~ p
alkyloxyalkoxy wherein alkyloxy is C ~ -C4 alkyloxy and alkoxy is C 1-C6
alkoxy; and
X represents O, NH or NR4 wherein R4 is C 1-C6 alkoxy, C I -Cb alkenyloxy, C7-
C; 6
arylalkyloxy wherein aryl is C6-C 1 p aryl and alkyloxy is C 1-C6 alkyloxy, C~-
C 16
arylalkenyloxy wherein the aryl is C6-C 1 p aryl and alkenyloxy is C 1-C6
alkenyloxy, C 1-C6
alkanoyloxy, C~-C 16 arylalkanoyloxy wherein aryl is C6-C 1 p aryl and
alkanoyoloxy is
C1-C6 alkanoyloxy.
SUBSTITUTE SHEET (RULE 26)

CA 02269910 1999-04-26
WO 98/22467 PCT/SE96/01497 _
4 -
The process for the preparation of the compounds of the general formula (I)
comprises the
following steps:
s (i) Naloxone (II), naltrexone (III} or oxymorphone (IIIa) of the formula
(ll): R = allyl
(III): R = cyclopropylmethyl
(111a): R = methyl
HL J
is reacted with phenylhydrazine hydrochloride in the presence of an acid,
preferably
to methanesulfonic acid, sulfuric acid or hydrochloric acid, giving
naloxindole (NLI))
naltrindole (NTI) or oxymorphindole (OMI), PS. Portoghese et al., J. Med.
Chem. Vol. 31:
281-282) l988) of the following formula:
NCR
OH NLI: R = allyl, X = NH
NTI: R = cyclopropylmethyl, X = NH
,,,~~~ , OMI: R = methyl, X = NH
or;
HO O
naloxone (II), naltrexone(III) or oxymorphone is reacted with O-phenyl-
hydroxyl amine
hydrochloride in the presence of an acid, preferably methanesulfonic acid,
sulfuric acid or
2o hydrochloric acid, giving the benzofurane derivatives NLB, naltriben (NTB;
P. S.
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98/22467 PCT/SE96/01497 -
.
Portoghese et al., J. Med. Chem., Vol. 34: 1715-1720, 1991 ) or OMB (US 5 223
507) of
the formula
NLB: R = allyl, X = O
NTB: R = cyclopropylmethyl, X = O
OMB: R = methyl, X = O
s (ii) the 3-hydroxy group is protected by alkylation with benzyl bromide,
methoxymethyl
bromide) ethoxymethyI bromide, trityl chloride or a silylating agent,
preferably dimethyl
isobutyl-silyl chloride, trimethylsilyl chloride, triethylsilyl chloride, t-
butyldimethylsilyl
chloride or tri-i-propylsilyl chloride, in a solvent, preferably N,N-
dimethylformamide,
dichloromethane or tetrahydrofurane, in the presence of a base which may not
be a weak
~ o base, preferably potassium carbonate, potassium hydroxide, sodium hydride,
sodium amide
or diisopropyl ethylamine, giving a compound of the formula (IV)
JiR~
OH
R20
~ s wherein
o~ uo> ,~~,
.,
R1 is allyl, cyclopropylmethyl or methyl;
R2 is benzyl, methoxymethyl, ethoxymethyl, trityl or silyl, preferably
dimethyl isobutyl silyl,
2o trimethylsilyl, triethylsilyl, t-butyldimethylsilyl or tri-i-propylsilyl;
and
SUBSTITUTE SHEET (RULE 26j
H(~ ,-



CA 02269910 1999-04-26
WO 98I22467 PCT/SE96/01497 _
6
X is NH, O, N-benzyl, N-methoxymethyl, N-ethoxymethyl, N-trityl or N-silyl,
preferably
dimethyl isobutyl silyl, trimethylsilyl, triethylsilyl, t-butyldimethylsilyl
or tri-i-propylsilyl;
(iii) the compound of the formula (IV ) is treated with C 1-C2 dialkyl
sulfates, C t -C~, alkyl
halides, C 1-C6 alkenyl halides, C~-C 16 aralkyl halides wherein the aryl is
C6-C 1 p aryl and
s the alkyl is C 1-C6 alkyl, C7-C 16 arylalkenyl halides wherein the aryl is
C6-C 1 p aryl and the
alkenyl is C2-C6 alkenyl, C2-C6 alkanoyl halides, C~-C ~ 6 arylalkanoyl
halides wherein the
aryl is C6-C ~ p aryl and the alkanoyl is C2-C~, aIkanoyl, in a solvent,
preferably N,N- -
dimethyl formamide or tetrahydrofurane, using a strong base, preferably sodium
hydride,
potassium hydride or sodium amide, giving a compound of the formula (V)
io
R1
o~ ,~o> ~~
R20
wherein
R ~ is allyl or cyclopropylmethyl;
is
R2 is benzyl, methoxymethyl, ethoxymethyl, trityl or silyl, preferably
dimethyl isobutyl silyl,
trimethylsilyl, triethylsilyl, t-butyldimethylsilyl or tri-i-propylsilyl; and
R3 is C 1-C6 alkyl, C I -C6 alkenyl; C~-C 16 arylalkyl wherein the aryl is C6-
C 1 p aryl and the
zo alkyl is C 1-C6 alkyl; C7-C ~ 6 arylalkenyl wherein the aryl C6-C 1 p aryl
and the alkenyl is C 1-
C6 alkenyl; C 1-C6 alkanoyl, C~-C 16 arylalkanoyl wherein the aryl is C6-C I p
aryl and the
alkyl is C t -C6 alkyl;
X is as defined in the formula (IV) above; and
is
SUBSTITUTE SHEET (RULE 26)

CA 02269910 1999-04-26
WO 98I22467 PCTlSE9610149? _
7
optionally the following step (iv) whereby
(iv) the compound of the formula (V) wherein X is NH, O, N-benzyl, N-
methoxymethyl, N
ethoxymethyl, N-trityl or silyl, preferably dimethyl isobutyl silyl,
trimethylsilyl, triethylsilyl,
s t-butyldimethylsilyl or tri-i-propylsilyl;
is hydrolized in diluted acids, preferably hydrochloric acid or sulfuric acid,
optionally in the
presence of a solvent, preferably an alcohol, and in particular methanol,
ethanol or n-
propanol, giving a compound of the formula (VI)
~n1
R3
o~ ,~o> ,~~,
HO \O ,,
wherein R ~ , and R3 are as defined above in formula ( V ), and X is NH, O ar
N-benzyl; and
is (v) the compound of the formula (VI) is alkylated or acylated, giving a
compound of the
formula (I).
Detailed description of the invention
2o The invention will now be described in more detail by the following
examples.
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98I22467 PCT/SE96101497
8
EXAMPLES
Example 1
Synthesis of 17-(CycIopropylmethyl)-6,7-dehydro-4,5a-epoxy-14-hydroxy-3-
s (methoxymethoxy)-6,7-2',3'-benzo[b)furanomorphinan (compound 1).
Sodium hydride (426 mg, 17.7 mmol; obtained from 710 mg of sodium hydride
dispersion
in oil by washings with n-hexane) was added to a solution of naltriben
methanesulfonate
(2.0 g, 3.9 mmol) in 30 ml of anhydrous N,N-dimethyl formamide at 0~ C. The
resulting
i o mixture was stirred at 0~ C for 20 min and then at room temperature for
another 60 min.
After cooling to 0~ C, methoxymethyl bromide (653 pl, 8 mmol) was added and
stirnng was
continued for 15 min at 0~ C and then for additional 120 min at room
temperature. Excess
sodium hydride was destroyed by addition of methanol and H20. The resulting
mixture was
extracted with ethyl acetate (4 x 50 ml), the combined organic layers were
washed with
is H20 (2 x 50 ml) and brine, dried over Na2S04 and evaporated to give an oil
which was
crystallized from MeOH to yield 1.0 g (56%) of compound 1. M. p. l29-130~ C.
~ H-NMR (CDC13): S 7.45 (d, J = 8.3 Hz, I atom. H), 7.37 (d, J = 8.3 Hz, 1
atom. H), 7.25
(m, 1 arom.H), 7.l6 (m, 1 atom.), 6.86 (d, J = 8.3 Hz, 1 atom. H), 6.60 (d, J
= 8.3 Hz, I
2o atom. H), 5.63 (s, H-C(5)), 5.17 and 5.06 (2 d, J = 6.6, 6.6 Hz, OCH20),
3.42 {s, CH30).
Analysis calculated for C2gH29N05. 0.2 MeOH {465.95): C 72.69, H 6.45, N 3.01;
found:
72.58, H 6.28, N 3.00.
zs Example 2
Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-14-hydroxy-3-
(methoxymethoxy)-6,7-2',3'-(N-methoxymethylindolo)morphinan (compound 2).
Sodium hydride (492 mg, 20.5 mmol; obtained from 820 mg of 60% dispersion in
oil by
3o washings with n-hexane) was added to a solution of naltrindole
hydrochloride ( 1.5 g, 3.3
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98I22467 PCT/SE96/01497
9
mmol) in 30 m1 of anhydrous N,N-dimethyl formamide at 0~ C. After stirring at
0~ C for 15
min and additional 30 min at room temperature, the mixture was cooled again to
0~ C and
methoxymethyl bromide ( 1.27 g) 10.2 mmol) was added. After stirring at 0~ C
for 30 min,
stirring was continued for another 120 min at room temperature. Methanol and
H20 were
s added to destroy excess of sodium hydride. The mixture was extracted with
ehtyl acetate (3
x 60 ml), the combined organic layers were washed with H20 (2 x 50 ml) and
brine (2 x 50
ml) and evaporated to give a yellowish oil which was purified by column
chromatography
(silica gel, elution with CH2C12/MeOH/conc. NH40H 245:10:1) to afford 500 mg
(30%)
pure compound 2 as a colorless foam.
~o
~H NMR (CDC13): S 7.44 (m, 2 arom. H), 7.20 (m, 1 arom. H), 7.07 (m, 1 arom.
H)) 6.82
(d, J = 8 Hz, 1 arom. H), 6.58 (J = 8 Hz), 5.81 (s, H-C(5)), 5.79 and 5.50 (2
d, J = 10.8,
10.8 Hz, NCH2O) 5.12 and 5.50 (2 d, J = 6.4, 6.4 Hz, OCH20), 3.41 and 3.33 (2
s,
CH30).
Analysis calculated for C3pH34N205 (502.61): C 7l.69, H 6.82, N 5.57; found: C
71.92, H
6.94, N 5.34.
Example 3
zo Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-14-(2',6'-
dichlorobenzyloxy)-4,5a
epoxy-3-(methoxymethoxy)-6,7-2',3'-benzo[b]furanomorphinan (compound 3).
Sodium hydride (36 mg, 1.5 mmol; obtained from 60 mg of 60% sodium hydride
dispersion
in oil by washings with n-hexane) was added to a solution of compound 1 (300
mg, 0.65
zs mmol) in 8 ml of anhydrous N,N-dimethylformamide at 0~ C. After stirring at
0~ C for 15
min, stirring was continued for another 30 min at room temperature and the
mixture was
cooled again to 0~ C. 2,6-Dichlorobenzyl bromide (240 g, 1 mmol) was added at
once and
stirring was continued for 15 min at 0~ C and then for 3 h at room
temperature. Excess
sodium hydride was destroyed with MeOH and H20 and the mixture was extracted
with
so ethyl acetate (3 x 30 ml). The combined organic layers were-washed with H20
(2 x 30 ml)
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98I22467 PCT/SE96/01497
and brine (2 x 30 ml), dried over Na2S04 and evaporated. The residue (400 mg
colorless
oil) was crystallized from MeOH to yield 300 mg (75%) of compound 3. M. p. l80-
182~ C.
1H NMR (CDC13): 8 7.41 (d, J = 8.3 Hz, 1 atom. H), 7.33 (d, J = 8.3 Hz, 1
atom. H), 7.23
s (m, 1 atom. H), 7.14 (m, 2 atom. H), 7.03 and 7.01 (2 d, J = 7.3, 7.3 Hz, 2
atom. H), 6.84
(d, J = 8.3 Hz, 1 atom. H), 6.59 (d, J = 8.3 Hz, 1 atom. H), 5.56 (s, H-C(5)},
5.32 and 4.68
(2 d, J = 8.7, 8.7 Hz, OCH2Ph), 5.16 and 5.05 (2 d, J = 6.6, 6.6 Hz, OCH20),
3.41 (s,
CH30).
~o Example 4
Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-14-(2',6'-dichlorobenzyloxy)-
4,5a-
epoxy-3-hydroxy-6,7-2',3'-benzo[b]furanomorphinan (compound 4).
A solution of compound 3 ( 150 mg, 0.24 mmol) in MeOH (4 ml) and 1 N HCl (2
ml) was
i s refluxed for 1 h. After cooling, the solution was alkalized with cone.
NH40H, extracted
wiht ethyl acetate (3 x 15 ml), the combined organic layers were washed with
H20 (2 x 15
ml) and brine ( 10 ml), dried over Na2S04 and evaporated to give an oily
residue which was
crystallized from MeOH to yield 70 mg (51 %) of compound 4. M. p. l93-l95~ C
(dec.}.
1H NMR (CDC13): 8 7.42 (d, J = 8.3 Hz, 1 atom. H), 7.33 (d, J = 8 Hz, 1 atom.
H), 7.24
(m, 1 atom. H), 7.14 (m, 2 atom. H), 7.03 and 7.01 (2 d, J = 7.3 Hz, 1 atom.
H), 6.64 (d, J
= 8.1 Hz, 1 atom. H), 6.56 (d, J = 8.1 Hz, 1 atom. H), 5.58 (s, H-C(5)), 5.32
and 4.68 (2 d,
J = 8.6 Hz, OCH2Ph).
is Analysis calculated for C33H29C12N04 (574.51 ): C 68.79, H 5.09, N 2.44;
found: C 68.97,
HS.OS,N2.44.
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98/22467 PCT/SE96/01497 -
11
Example 5
Synthesis of 17-(Cyclopropylmethyl) -6,7-dehydro-4,5a-epoxy-3-(methoxymethoxy)-
14-
(3'-nitrobenzyloxy)-6,7-2',3'-benzojb]furanomorphinan (compound 5).
s Sodium hydride {36 mg, 1.5 mmol; obtained from 60 mg of 60~lo sodium hydride
dispersion
in oil by washings with n-hexane) was added to a solution of compound 1 (300
mg, 0.65
mmol) in 6 m1 of anhydrous N,N-dimethylformamide at 0~ C. The resulting
mixture was
stirred at 0~ C for 15 min and then at room temperature for another 30 min.
After cooling to
0~ C, 3-nitrobenzyl bromide (216 mg, 1 mmol) was added and stirring was
continued first
i o at 0~ C for 15 min and then at room temperature for 3 h. Excess sodium
hydride was
destroyed by addition of MeOH and H20. The resulting mixture was extracted
with ethyl
acetate (3 x 30 ml), the combined organic layers were washed with H20 (2 x 20
ml) and
brine (2 x 20 ml), dried over Na2S04 and evaporated to give 380 mg of a brown
oil which
was purified by column chromatography {silica gel, elution with
CH2Cl2/MeOH/conc.
~ s NH40H 240:10:1 ) to afford I00 mg (26% ) of compound 5 as colorless foam.
1H NMR (CDC13): b 8.25 (s, 1 arom. H), 7.99 (m, 1 arom. H), 7.55 (d, J = 7.8
Hz, 1 arom.
H), 7.47 (d) J = 8.3 Hz, 1 arom. H), 7.28 (m, 4 arom. H), 7.15 (m, 1 arom. H),
6.87 (d, J =
8.3 Hz, 1 arom. H), 6.62 (d, J = 8.3 Hz, 1 arom. H), 5.66 (s, H-C(5)), 5.17
and S.07 (2 d, J
20 = 6.6 Hz) OCH20, 4.92 and 4.44 (2 d, J = 11.5 Hz, OCH2Ph), 3.42 (s, CH30).
Example 6
Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-hydroxy-14-(3'-
nitrobenzyloxy)-6,7-2',3'-benzojb]furanomorphinan Hydrochloride (compound 6).
zs
A solution of compound 5 (80 mg, 0.13 mmol) in MeOH (4 ml) and 1N HCl (2 ml)
was
refluxed for 1 h. After cooling, the solution was alkalized with conc. NH40H,
extracted
with ethyl acetate (3 x 20 ml), the combined organic layers were washed with
H20 (2 x 15
ml) and brine (15 ml), dried over Na2S04 and evaporated. The oily residue was
dissolved in
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98/22467 PCT/SE96/OI497 -
12
acetone and transformed into the hydrochloride salt (compound 6) by addition
of ethereal
HCI. Yield 50 mg (66%). M. p. > 230~ C (dec.).
1 H NMR (DMSO-d6): S 9.40 (s, OH), 9.15 (broad s, +NH), 7.84 (s, 1 atom. H),
7.60 (d, J
s = 8.8 Hz, 1 atom. H), 7.53 (d, J = 7.6 Hz, 1 atom. H), 7.45 (d, J = 8 Hz, 1
atom. H), 7.23
(d, J = 7.6 Hz, 1 atom. H), 7.19 (d, J = 7.6 Hz, 1 atom. H), 6.98 (m, 1 atom.
H), 6.88 (d, J
= 7.6 Hz, 1 atom. H), 6.69 (d, J = 8.3 Hz, 1 atom. H), 6.66 (d, J = 8.3 Hz, 1
atom. H), 6.03
(s, H-C(5)), 4.98 and 4.87 (2 d, J = 14, 14 Hz, OCH2Ph).
~ o Analysis calculated for C33H3pN206 x HCl (587.08): C 67.52, H 5.32, N.
4.77; found: C
67.78, H 5.25, N 4. 76.
Example 7
Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,Sa-epoxy-3-(methoxymethoxy)-
14-(2-
~ s naphthylmethoxy)-6,7-2',3'-benzo[b]furanomorphinan (compound 7).
Sodium hydride (36 mg, 1.5 mmol; obtained from 60 mg of sodium hydride
dispersion in oil
by washings with n-hexane) was added to a solution of compound 1 (300 mg, 0.65
mmol)
in 5 m1 of anhydrous N,N-dimethylformamide at 0~ C. The resulting mixture was
stirred at
20 0~ C for 15 min and then at room temperature for another 30 min. After
cooling to 0~ C, 2-
(bromomethyl)naphthalene (22l mg) 1 mmol) was added and stirring was continued
at first
at 0~ C for 1 S min and then at room temperature for 2 h. Excess sodium
hydride was
destroyed by addition of MeOH and H20. The resulting mixture was extracted
with ethyl
acetate (3 x 30 ml), the combined organic layers were washed with H20 (2 x 20
ml) and
2s brine (2 x 10 ml), dried over Na2S04 and evaporated to give a crystalline
residue which
was recrystallized to yield 285 mg (73%) of compound 7. M. p. 198-201~ C.
1H NMR (CDC13): 8 7.72-7.08 (m, 11 atom. H), 6.86 (d, J = 8.3 Hz, 1 atom. H),
6.62 (d, J
= 8.3 Hz, 1 atom. H), 5.68 (s, H-C(5)), 5.17 and 5.07 (2 d, J = 6.6, 6.6 Hz,
OCH20), 5.01
so and 4.57 (2 d, J = 11.2) 11.2 Hz, OCH2Ar), 3.42 (s, CH30):
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98J22467 PCTJSE96J01497-
13 -
Analysis calculated for C39H3~N05 x 0.2 EtOAc (C4Hg02~ (617.35): C77.43, H
6.30, N
2.27; found: C 77.40, H 6.27, N 2.27.
s Example 8
Synthesis of 17-(Cyclopropyimethyl)-6,7-dehydro-4,5a-epoxy-3-hydroxy-14-(2'-
naphthylmethoxy)-6,7-2',3'-benzo[b]furanomorphinan hydrochloride(compound 8).
A solution of compound 7 ( 180 mg, 0.3 mmol) in MeOH (5 ml) and 1N HCl (3 ml)
was
~ o refluxed for 30 min, cooled and kept in the refrigerator overnight. The
crystals formed were
isolated and washed with small amounts of MeOH and ether to yield 150 mg (84%)
of
compound 8. M. p. > 215~ C.
~ H NMR (DMSO-d6): 8 9.42 (s, OH), 9.00 (broad s, +NH), 7.68-6.85 (m, 11 arom.
H),
is 6.71 (d, J = 8 Hz, 1 arom. H), 6.67 (d, J = 8 Hz, 1 arom. H), 6.04 (s, H-
C(5)), 4.92 (s,
OCH2Ar).
Analysis calculated for C3~H33N04 x HCI. 0.3 MeOH (60l.75): C74.45, H 5.90, N
2.33;
found: C 74.47, H 5.76, N 2.3S.
2o Example 9
Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,Sa-epoxy-14-(2'-
fluorobenzyloxy)-3-
(methoxymethoxy)-6,7-2',3'-benzo[b]furanomorphinan (compound 9}.
Sodium hydride (36 mg, 1.5 mmol; obtained from 60 mg of 60% sodium hydride
dispersion
2s in oil by washings with n-hexane) was added to a solution of compound 1
(300 mg, 0.65
mmol) in 5 ml of anhydrous N,N-dimethylformamide at 0~ C. The resulting
mixture was
stirred at 0~ C for 10 min and the at room temperature for another 30 min.
After cooling to
0~ C, 2-flourobenzyl bromide ( 120 ~.1, 1 mmol) was added and stirring was
continued at
first at 0~ C for 15 min and then at room temperature for 2 h. Excess sodium
hydride was
3o destroyed by addition of MeOH and H20. The resulting mixture was extracted
with ethyl
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98/22467 PCT/SE96/01497 -
14
acetate (3 x 30 ml), the combined organic layers were washed with H20 (2 x 20
ml) and
brine (2 x 20 ml), dried over Na2S04 and evaporated to give an oil which
purified by
column chromatography (silica gel, elution with ethyl acetate/n-hexane 1 ) 1:3
2) 1:1 ) to
afford 215 mg (58%) of compound 9 as colorless foam.
s
io
I H NMR (DMSO-d6): b 7.56 (d, J = 8 Hz, 1 atom. H), 7.49 (d, J = 8 Hz, 1 atom.
H), 7.31
(m, 1 atom. H), 7.21 (m, 1 atom. H), 6.8l (d, J = 8.4 Hz, 1 atom. H), 6.67 (d,
J = 8.4 Hz),
5.72 (s, H-C(5}), 5.06 and 5.01 (2 d, J = 6.4, 6.4 Hz, OCH20), 4.89 and 4.57
(2 d, J =
11.6, 11.6 Hz, OCH2Ph), 3.33 (s, CH30).
Analysis calculated for C35H34NO5 (5b7.66): C 74.06, H 6.04, N 2.47; found: C
73.7l, H
5.92, N 2.42.
Example 10
is Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-14-(2'-
fluorobenzyloxy)-3-
hydroxy-6,7-2',3'-benzo[b)furanomorphinan Hydrochloride (compound 10).
A solution of compound 9 ( 160 mg, 0.28 mmol) in MeOH (3 ml) and 1 N HCI (3
ml) was
refluxed for 20 min, then cooled and kept in the refrigerator overnight. The
crystals formed
zo were isolated and washed with small amounts of MeOH and ether to yield 110
mg (70%) of
compound 10. M. p. > 215~ C.
1 H NMR (CDC13): 8 9.45 (s, OH), 9.04 (broad s, +IVH), 7.54 (d, J = 8.4 Hz, 1
atom. H,
7.31-6.73 (m, 7 atom. H), 6.71 (d, J = 8.2 Hz, 1 atom. H), 6.66 (d, J = 8.2
Hz, 1 atom. H),
zs 5.98 (s, H-C(5)), 4.81 and 4.84 (2 d, J = 12 Hz, OCH2Ph).
Analysis calculated for C33H3pFNO4 x HCI. 1.4 H20 (585.29): C 67.72, H 5.82, N
2.39;
found: C 67.63, H 5.56, N 2.51.
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98l22467 PCT/SE96/01497
Example 11
Synthesis of 14-(Cinnamyloxy)-17-(cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-
(methoxymethoxy)-6,7-2',3'-benzo[b]furanomorphinan (compound 11 ).
s Sodium hydride {36 mg, 1.5 mmol; obtained from 60 mg of 60% sodium hydride
dispersion
in oil by washings with n-hexane) was added to a solution of compound 1 (300
mg, 0.65
mmol) in 5 mi of anhydrous N,N-dimethylformamide at 0~ C. The resulting
mixture was
stirred at 0~ C for 15 min and then at room temperature for another 30 min.
After cooling to
0~ C, cinnamyl bromide ( 197 mg, 1 mmol) was added and stirring was continued
first at 0~
i o C for I O min and then at room temperature for 2 h. Excess sodium hydride
was destroyed
by addition of MeOH and H20. The resulting mixture was extracted with ethyl
acetate (3 x
30 ml)> the combined organic layers were washed with H20 (2 x 20 ml) and brine
( I x 20
ml), dried over Na2S04 and evaporated to give a crystalline residue which was
treated with
boiling methanol to afford 200 mg (53%) of compound I I. M. p. I56-159~ C.
~s
zo
1H NMR (CDCl3): 8 7.47 (d, J = 8 Hz, I arom. H), 7.33 (d, J = 8 Hz, 1 arom.
H), 7.28-
7.07 (m, 7 arom. H), 6.84 (d, J, 8.4 Hz, 1 arom. H), 6.59 (d, J = 8.4 Hz, I
arom. H), 6.38
(d, 3 = 16 Hz, I olef. H), 6.13 (m, 1 olef. H), 5.68 (s, H-C(5)), 5.I6 and
5.06 (2 d, J = 6.4,
6.4 Hz) OCH20), 4.46 and 4.11 (2 m, CH20-C( 14)), 3.42 (s, CH30).
Analysis calculated for C3~H3~NOg. 0. I EtOAc (584.52): C 76.85, H 6.52, N
2.40; found:
C 76.70, H 6.48, N 2.41.
Example 12
is Synthesis of 14-(Cinnamyloxy)-17-(cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-
3-
hydroxy-6,7-2',3'-benzo[b]furanomorphinan Salicylate (compound 12).
A solution of compound 11 (160 mg, 0.28 mmol) in MeOH (3 ml) and 1N HCl (3 ml)
was
refluxed for 1 h. After cooling, the solution was alkalized with conc. NH40H,
extracted
3o with ethyl acetate (3 x 15 ml), the combined organic layers were washed
with H20 (2 x 15
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98/22467 PCT/SE96/01497 -
16
ml) and brine ( 10 ml), dried over Na2S04 and evaporated to give a colorless
foam ( 100
mg). To a solution of this foam in a small amount of methanol 30 mg of
salicyclic acid were
added, the crystals formed collected and washed with cold methanol to yield
100 mg (53%)
~
of compound 12. M. p. > 170 C.
s
1 H NMR (CDCl3): 8 7.94 (d, J = 8 Hz, 1 arom. H), 7.35 (d, J = 8 Hz, 1 arom.
H), 7.30-
6.73 (m, 12 arom. H), 6.56 {d, J = 8 Hz, 1 arom. H), 5.96 (s, 2 olef. H), 5.55
(s, H-C(5)),
4.33-4.02 (m, CH20-C(14)).
io Analysis calculated for C35H33N0~. Salicyclic acid (C~H~03). I MeOH
(701.82): C 73.57,
H 6.18, N 2.00; found: C 73.56, H S.96, N 2.06.
Example 13
Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-14-methoxy-3-
is (methoxymethoxy)-6,7-2',3'-benzo[b]furanomorphinan (compound 13).
Sodium hydride (36 mg, 1.5 mmol; obtained from 60 mg of 60% sodium hydride
dispersion
in oil by washings with n-hexane) was added to a solution of compound I (300
mg, 0.65
mmol) in 5 m1 of anhydrous N,N-dimethylformamide at 0~ C. The resulting
mixture was
2o stirred at 0~ C for 15 min and the at room temperature for another 30 min.
After cooling to
0~ C, dimethyl sulfate ( 100 ~.1, 1 mmol) was added and stirring was continued
at first at 0~
C for 15 min and then at room temperature for 2 h. Excess sodium hydride was
destroyed
by addition of MeOH and H20. The resulting mixture was extracted with ethyl
acetate (3 x
30 ml), the combined organic layers were washed with H20 (2 x 20 ml) and brine
(2 x 20
2s ml), dried over Na2S04 and evaporated to give a colorless foam (280 mg) of
compound 13
which was pure by TLC and NMR.
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98l22467 PCT/SE96/01497 ,
17
1H NMR (DMSO-d6): 8 7.56 (d, J = 8 Hz, 1 atom. H), 7.S2 (d, J = 8 Hz, 1 atom.
H), 7.32
(dd, J = 8, 8 Hz, 1 atom. H), 7.23 (dd, J = 8, 8 Hz, I atom. H), 6.79 (d, J =
8.2 Hz, I atom.
H), 6.64 (d, J = 8.2 Hz, 1 atom. H), 5.64 (s, H-C(5)), 5.05 and 5.00 (2 d, J =
6.4, 6.4 Hz,
OCH20), 3.32 (CH30).
s
Analysis calculated for C29H31 N05. 0.2 MeOH (479.98): C 73.07, H 6.68, N
2.92; found:
C 72.94, H 6.60, N 2.92.
Example 14
~o Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-hydroxy-14-
methoxy-6,7-
2',3'-benzo[b]furanomorphinan Hydrochloride (compound 14).
A solution of compound 13 ( 160 mg, 0.28 mmol) in MeOH (3 ml) and 1 N HCI (2
ml) was
refluxed for 20 min, then cooled and kept in the refrigerator overnight. The
crystals formed
i s were isolated and washed with small amounts of MeOH and ether to yield 70
mg (36%) of
compound 14. M. p. > 240~ C.
I H NMR (DMSO-db): 8 9.47 (s, OH), 9.17 (broad s, ~NH), 7.61 (d, J = 8 Hz, 1
atom. H),
7.53 (d, J = 8 Hz, 1 atom. H), 7.36 (dd, J = 8, 8 Hz, 1 atom. H), 7.27 (dd, J
= 8, 8 Hz, I
2o atom. H), 6.72 (d, J = 8.4 Hz, 1 atom. H), 6.65 (d, J = 8.4 Hz, 1 atom. H),
5.90 (s, H-
C(5)), 3.35 (s, CH30).
Analysis calculated for C2~H2~N04 x HCI. 1.5 HZO (493.00): C 65.78, H 6.34, N
2.84;
found: C 65.89, H 6.20, N 2.85.
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98/22467 PCT/SE96/01497 -
18
Example 15
Synthesis of 17-(Cyclopropylmethyl)-14-(2'-chlorobenzyloxy}-6,7-dehydro-4,5a-
epoxy-3-
(methoxymethoxy)-6,7-2',3'-(N-methoxymethylindolo)morphinan (compound 15).
s Sodium hydride (36 mg, 1.5 mxnol; obtained from 60 mg of 60% sodium hydride
dispersion
in oil by washings with n-hexane) was added to a solution of compound 2 (327
mg, 0.65
mmol) in 5 m1 of anhydrous N,N-dimethylformamide at 0~ C. The resulting
mixture was
stirred at 0~ C for 1 S min and then at room temperature for another 30 min.
After cooling to
0~ C, 2-chlorobenzyl bromide (205 mg, 1 mmol) was added and stirring was
continued first
i o at 0~ C for 15 min and then at room temperature for 3 h. Excess sodium
hydride was
destroyed by addition of MeOH and H20. The resulting mixture was extracted
with ethyl
acetate (3 x 30 ml), the combined organic layers were washed with H20 (2 x 40
ml) and
brine (2 x 30 ml), dried over Na2S04 and evaporated to give 370 mg of compound
15 as
colorless foam which was pure by TLC and NMR.
is
1H NMR (CDC13): 8 7.56 (m, 1 arom. H), 7.44 (m, 1 arom. H), 7.37-7.17 (m, 3
arom. H),
7.01 (m, 1 arom. H), 6.9l (m, 1 arom. H), 6.83 (d, J = 8.2 Hz, 1 arom. H),
6.59 (d, J = 8.2
Hz, 1 arom. H), 5.90 (s, H-C(5)), 5.82 and 5.55 (2 d, J = 11.2, 11.2 Hz,
NCH20), 5.l3 and
5.03 (2 d, J = 6.4, 6.4 Hz, OCH20), 4.98 and 4.56 (2 d, J = 13, 13 Hz,
OCH2Ph), 3.40 and
zo 3.26 (2 s, 2 CH30).
Example 16
Synthesis of 17-(Cyclopropylmethyl)-14-(2'-chlorobenzyloxy)-6,7-dehydro-4,5a-
epoxy-3-
hydroxy-6,7-2',3'-indolomorphinan Hydrochloride (compound 16).
zs
A solution of compound 15 (300 mg, 0.48 mmol) in MeOH (5 ml) and IN HCl (3 ml)
was
refluxed for 1 h. After cooling, the solution was alkalized with conc. NH40H,
extracted
with ethyl acetate (3 x 20 ml), the combined organic layers were washed with
H20 (2 x 20
ml) and brine (20 ml), dried over Na2S04 and evaporated to give a colorless
oil. To a
so solution of this foam in a small amount of methanol ethereal HCl was added,
the crystals
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98I22467 PCT/SE96/01497
19
formed collected and washed with cold methanol to yield l20 mg (43%) of
compound 16.
M. p. > 250~ C (dec.).
1 H NMR (DMSO-d6): 8 11.38 (s, NH), 9.38 (s, OH), 8.76 (broad s, ~NH), 7.34-
6.85 (m, 8
s atom. H), 6.72 (d, J = 8 Hz, 1 atom. H), 6.64 (d, J = 8 Hz, I atom. H), 5.93
(s, H-C(5)),
4.80 and 4.67 (2 d, J = 13, 13 Hz, OCH2Ph).
Analysis calculated for C33H31N2O3 x HCI. (575.S4): C 68.87, H 5.60, N 4.87;
found: C
68.81, H 5.59, H 4.77.
io
Example 17
Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-3,14-dimethoxy-4,5a-epoxy-6,7-
2',3'-
benzo[b]furanomorphinan (compound 17).
i s Sodium hydride ( l44 mg, 6 mmol; obtained from 240 mg of 60% sodium
hydride dispersion
in oil by washings with n-hexane) was added to a solution of naltriben methane-
sulfonate
(500 mg, 0.97 mmol) in 10 m1 of anhydrous N,N-dimethylformamide at 0~ C. The
resulting
mixture was stirred at 0~ C for 15 min and then at room temperature for
another 30 min.
After cooling to 0~ C, dimethyl sulfate (380 pl, 4 mmol) was added and
stirring was
2o continued first at 0~ C for 30 min and then at room temperature for 3 h.
Excess sodium
hydride was destroyed by addition of MeOH and H20. The resulting mixture was
extracted
with ethyl acetate (3 x 40 ml), the combined organic layers were washed with
H20 (2 x 30
ml) and brine (2 x 30 ml), dried over Na2SOq and evaporated to give a
crystalline residue
which was recrystallized from MeOH to afford 320 mg (74%) of compound 17. M.
p. 221-
zs 224~ C (dec.).
~H NMR (CDCI3): S 7.47-7.14 (m, 4 atom. H), 6.64 (d, J = 8.4 Hz, 1 atom. H),
6.S9 (d, J
= 8.4 Hz, 1 atom. H), 5.62 (s, H-C(5)), 3.78 (s, CH30-C(3)), 3.31 (s, CH30-C(
14)).
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98/22467 PCT/SE96/01497
Analysis calculated for C2gH29N04. 0.3 MeOH (453.16): C 75.01, H 6.72, N 3.09;
found:
C 74.97, H 6.68) N 3.05.
Example 18
s Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-hydroxy-14-(3'-
chlorobenzyloxy)-6,7-2',3'-benzo[b]furanomorphinan Hydrochloride (compound
19).
To a stirred solution of naltriben methanesulfonate (256 mg, 0.5 mmol) in
anhydrous N,N-
dimethyl formamide ( 10 ml) was added sodium hydride (60% dispersion in oil,
60 mg, 1.5
~ o mmol) at 0~ C. The solution was stirred for 1 h at 20~ C and then cooled
to 0~ C prior to
addition of bromomethyl methyl ether ( 125 mg, 1.0 mmol). The mixture was
warmed up to
room temperature during 1 h and cooled again to 0~ C before sodium hydride
(60%
dispersion in oil, l00 mg, 2.5 mmol) was added. After 1 h, 3-chlorobenzyl
bromide (308
mg, 1.5 mmol) was added to the solution and the resulting mixture was stirred
for 4 h at 20~
~ s C, and then 5 m1 of methanol and 5 ml ethyl acetate were slowly added at
0~ C, followed by
addition of saturated aqueous NH4C1 solution (20 ml). The mixture was
extracted with
ethyl acetate (3 x 50 ml), the combined organic layers were washed with brine,
dried over
MgS04; and evaporated to give crude 17-(cyclopropylmethyl)-6,7-dehydro-4,5a-
epoxy-3-
(methoxymethoxy)-14-(3'-chlorobenzyloxy)-6,7-2', 3'-benzo[b]furanomorphinan
20 (compound 18). This crude product was dissolved in 5 m1 of ethanol and 1.5
ml of 1 N
hydrochloric acid and refluxed for 1 h. The reaction mixture was alkalized
with 1N aqueous
NH40H solution) extracted with ethyl acetate (3 x 50 ml), the combined organic
layers
were washed with brine, dried over MgS04, and concentrated to give a crude
product
which was purified by silica gel column chromatography (hexane: CHCl3
zs (75:25-Q50:50-~25:75~ l00:0) -~CHCI3:AcOEt {80:20-Q50:50--Q0:100) to afford
the title
compound as the free base (colorless oil; 232 mg, 86%). 1 H NMR (CDCl3): 8
7.50-7.05
(m, 8 arom. H), 6.69 (d, J = 8.4 Hz, 1 arom. H), 6.58 (d, J = 8.4 Hz, 1 arom.
H), 5.68 (s,
H-C(5)), 4.81 and 4.35 (2 d, J = 11.6, 11.6 Hz, OCH2(3'-CIPh)). A solution of
this free
base in anhydrous diethyl ether (5 ml) was treated with HCl/ether solution
(1M, 2 ml) at 0~
so C. Isolation of the precipitate provided the title compound 19 as a solid.
M. p. >230~ C
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98I22467 PCTlSE96/01497 ,
21
(dec.). IH NMR (DMSO-d6): 8 9.40 (s, OH), 8.59 (broad s, +NH), 7.53-6.90 (m, 8
atom.
H), 6.65 (s, 2 atom. H) 6.03 (s, H-C(5)), 4.74 and 4.62 (2 d, J = 13.6, l3.6
Hz, OCH2(3'-
C1PH)). Analysis calculated for C33H3pCIN04. HCI. 1.5 H20: C 65.67, H 5.68, N
2.32;
found: C 65.31, H 5.37, N 2.33.
Example 19
Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-hydroxy-14-(2'-
chlorobenzyloxy)-6,7-2',3'-benzo[b]furanomorphinan Hydrochloride (compound
21).
i o To a stirred solution of naltriben methanesulfonate (256 mg, 0.5 mmol) in
anhydrous N,N-
dimethyl formamide ( 10 mI) was added sodium hydride (60% dispersion in oil,
I00 mg, 2.5
mmol) at 0~ C. The solution was stirred for 1 h at 20~ C and then cooled to 0~
C prior to
addition of bromomethyl methyl ether ( 125 mg, 1.0 mmol). The mixture was
warmed up to
room temperature during 1 h and cooled again to 0~ C before sodium hydride
(60%
i s dispersion in oil, 100 mg, 2.5 mmol) was added. After 1 h, 2-chlorobenzyl
bromide (205
mg, 1.0 mmol) was added to the solution and the resulting mixture was stirred
for 12 h at
20~ C, and then 5 m1 of methanol and 5 ml ethyl acetate were slowly added at
0~ C,
followed by addition of saturated aqueous NH4Cl solution (20 ml). The mixture
was
extracted with ethyl acetate (3 x 50 ml)) the combined organic layers were
washed with
2o brine, dried over MgS04, and concentrated to give crude 17-
(cyclopropylmethyl)-'6,7-
dehydro-4,5a-epoxy-3-(methoxymethoxy)-14-(2'-chlorobenzyloxy)-6,7-2', 3'-
benzo[b]furanomorphinan (compound 20). This crude product was dissolved in 5
m1 of
ethanol and 2 m1 of 1 N hydrochloric acid and refluxed for 2 h. The reaction
mixture was
alkalized with 1N aqueous NH40H solution, extracted with ethyl acetate (3 x 50
ml), the
is combined organic layers were washed with brine, dried over MgS04, and
evaporated to
give a crude product which was purified by silica gel column chromatography
(hexane:
CHC13 (75:25-~50:50~25:75--~ 100:0) to afford the title compound as the free
base
(colorless oil; 236 mg, 87%). 1H NMR (CDC13): 8 7.45-6.90 (m, 8 atom. H), 6.72
(d, J =
8.4 Hz, 1 atom. H), 6.68 (d, J = 8.4 Hz, 1 atom. H), 5.72 (s, H-C(5)), 4.96
and 4.55 (2 d, J
so = 11.6, 11.6 Hz, OCH2(2'-CIPh)). A solution of this free base in (5 ml) of
anhydrous
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98/22467 PCT/SE96/01497 _
22
diethyl ether was treated with HC1/ether solution (1M, 2 ml) at 0~ C.
Isolation of the
precipitate provided the title compound as a solid. M. p. >220~ C.
IH NMR (DMSO-d6): 8 9.40 (s, OH), 8.59 (broad s, +NH), 7.56-6.90 (m, 8 arom.
H), 6.66
s (s, 2 arom. H) 6.03 (s, H-C(5)), 4.74 (s, OCH2(2'-CIPh)).
Analysis calculated for C33H3pC1NOq x HCI. 1.5 H20: C 65.67, H 5.68, N 2.32;
found: C
65.72, H 5.48, N 2.25.
i o Example 20
Synthesis of 14-Allyloxy-17-(cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-
hydroxy-I'-
allyl-6,7-2',3'-indolomorphinan Hydrochloride (compound 22).
Dimethyl isobutylsilyl chloride ( 114 mg, 0.75 mmol) was added at 0~ C to a
stirred solution
~ s of naltrindole methanesulfonate (255 mg, 0.5 mmol) and diisopropyl
ethylamine (260 mg,
2.0 mmol) in anhydrous N,N-dimethyl formamide ( 10 ml). The resulting solution
was stirred
at 20~ C for 1 h and then cooled to 0~ C prior to the addition of sodium
hydride (60%
dispersion in oil, l20 mg, 3.0 mmol). After I h, dimethyl isobutylsilyl
chloride ( 1 I 4 mg,
0.75 mmol) was added to the mixture. The resulting mixture was stirred for I h
at 20~ C
2o and then cooled to 0~ C before adding sodium hydride (60% dispersion in
oil, 120 mg, 3.00
mmol). After 1 h allyl bromide ( 1.51 mg, 1.25 mmol) was added. The reaction
mixture was
stirred for 2 h at 20~ C and then quenched with saturated aqueous NH4Cl
solution and
extracted with ethyl acetate (3 x 30 ml). The combined organic layers were
washed with
brine, dried over MgS04, and evaporated to give a yellow oil which was
dissolved in
2s methanol (6 ml) and 1 N hydrochloric acid (2 ml) and refluxed for 6 h. The
reaction mixture
was alkalized with 1N NH4OH solution, extracted with ethyl acetate (3 x 30
ml), the
combined organic layers were washed with brine, dried over MgS04, and
evaporated. This
crude product was purified by silica gel column chromatography (hexane: CHC13
(75:25-Q50:50) ~CHCI3:AcOEt-~ (75:25-Q50:50--~AcOEt) to give the title
compound as
so the free base (colorless oil; l06 mg).
SUBSTITUTE SHEET (RULE 2fi)


CA 02269910 1999-04-26
WO 98/22467 PCT/SE96/01497 ,
23
1H NMR (CDC13): S 7.40 (d, J = 8.4 Hz, 1 arom. H), 7.24 (m, 1 arom. H), 7.15
(m, 1
arom. H), 7.03 (m, 1 arom. H), 6.S7 (d, J = 8.4 Hz, 1 arom. H), 6.50 (d,J =
8.4 Hz, 1 arom.
H), 6.08 (m, 1 olef. H), 5.76 (m, 1 olef. H), 5.72 (s, H-C(S)), 5.15-4.75 (m,
6 H, CH2N, 2
s CH2 = C), 4.24 and 3.92 (2 dd, J = 12.4, 4.8 Hz, CH20).
The free base was dissolved in diethyl ether (S ml) and treated with HCl/ether
solution ( 1M,
2 ml) at 0~ C. Isolation of the precipitate provided the title compound 22 as
a solid.
~ o Example 21
Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,Soc-epoxy-3-hydroxy-I4-
allyloxy-
6,7,2',3'-indolomorphinan Hydrochloride (compound 23)
To a stirred solution of naltrindole hydrochloride (220 mg, 0.5 mmol) in
anhydrous N,N-
i s dimethyl formamide ( 10 ml) was added sodium hydride (60% dispersion in
oil, l60 mg, 4.0
mmol) at 0~C. The solution was stirred for 1 h at 20~ C, and then cooled to 0~
C prior to
addition of bromomethyl methyl ether (2S0 mg, 2.0 mrnol). The mixture was
warmed up to
r.t. during one hour and cooled again to 0~ C before sodium hydride (60%, 100
mg, 2.5
mmol) was added. After 1 h allyl bromide (242 mg, 2.0 mmol) was added to the
solution
zo and the resulting mixture was stirred for 4 h at 20~ C, and then 5 ml
methanol and S ml
ethyl acetate were slowly added at 0~ C, followed by addition of saturated
aqueous NH4C1
solution (20 mI). The mixture was extracted with ethyl acetate (3x50 ml), the
combined
organic layers were washed with brine, dried over MgS04, and evaporated to
give crude
product, which was dissolved in 5 ml ethanol/1 ml 6N hydrochloric acid and
refluxed for 2
is hrs. The reaction mixture was alkalized with 1 N aqueous NH40H solution,
extracted with
ethyl acetate (3.50 ml), the combined organic layers were washed with brine)
dried over
MgS04, and concentrated to give a crude product, which was purified by silica
gel column
chromatography (Hexane: CHC13 {75:2S-Q50:50-Q25:75--Q0:100) ~CHCl3: AcOEt
(75:2S--Q50:50-Q0:100)) to afford compound 23 (S3 mg, 23%) as the free base
(colorless
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98I22467 PCT/SE96101497 -
24
oil). 1 H NMR (CDC13): 8 7.50-7.00 (m, 4 arom. H), 6.65-6.45 (m, 2 arom. H),
5.80 (m,
1 H, CH=C), 5.75 (s, H-C(5)), 5.18-4.85 (m, C=CH2), 4.25 & 3.95 (m, OCH2).
A solution of this free base (53 mg) in anhydrous ethyl ether (5 ml) was
treated with
s HCl/ether solution ( 1M, 1 ml) at 0~ C. Isolation of the precipitate
provided the title
compound 23 as a solid (hydrochloride salt). M.p. 270-28S~ C (dec.). IR (HCl
salt, KBr)
3087 (m), 2846 (m), 1623 (s), 1505 (s), l462 (s), l330 (s), 1166 (s), 922 (s)
cm 1.
Example 22
io Synthesis of 17-Cyclopropylmethyl-6,7-dehydro-4,5oc-epoxy-3-hydroxy-14-
benzyloxy-
6,7,2',3'-benzo[b]foranomorphinan Hydrochloride (compound 24):
To a stirred solution of naltriben methanesulfonate (256 mg, 0.5 mmol) and N,N-

diisopropylethylamine (260 mg, 2.0 mmol) in anhydrous N,N-dimethyl formamide (
10 ml)
is was added triisopropylsilyl chloride (l45 mg, 0.75 mmol) at 0~C. The
solution was stirred
for 1 h at 20~ C, and then cooled to 0~ C prior to addition of sodium hydride
(60%, 120
mg, 3.0 mmol) was added. After 1 h, benzyl bromide ( 171 mg, 1.0 mmol) was
dropwise
added to the solution. The resulting mixture was stirred for 2 h at 20~ C, and
then 5 m1
methanol and 5 ml ethyl acetate were slowly added at 0~ C. After 30 min the
mixture was
2o extracted with ethyl acetate (3x50 ml). The combined organic layers were
washed with
brine, dried over MgS04, and concentrated to a yellow oil, which was purified
by silica gel
column chromatography {Hexane: CHCl3 (75:25--Q60:40)--Hexane: AcOEt
(75:25-Q50:50)) to afford compound 24 (206 mg, 82%) as the free base
(colorless oil). 1 H
NMR (CDC13): S 7.60-7.05 (m, 9 arom. H), 6.80-6.60 (m, 2 arom. H), 5.72 (s, H-
C(5)),
is 4.95 and 4.52 (2 d, J=11.6) 11.6 Hz, OCH2Ph).
A solution of this free base in anhydrous ethyl ether (5 ml) was treated with
HCl/ether
solution (1M, 1 ml) at 0~ C. Isolation of the precipitate provided the title
compound 24 as a
solid (hydrochloride salt). M.p. 255-270~ C (dec.). IR (HCl salt, KBr) 3642
(m), 3l74 (s),
so 293b {s), 1616 (s), 1500 (s)) 1457 (s), 1309 (s), 1068 (s), 932 (s) cm 1.
Analysis calculated
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98I22467 PCTlSE96/0149? _
_ 25
for C33H31 N04. HC1. 0.80 H20: C 71.23, H 6.09, N, 2.52. Found: C 71.32; H
5.78, N
2.35.
Example 23
s Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-hydroxy-14-
allyloxy-
6,7,2',3'-benzo(b]foranomorphinan Hydrochloride (compound 25)
To a stirred solution of naltriben methanesulfonate (256 mg, 0.5 mmol) and N,N-

diisopropylethylamine (260 mg, 2.0 mmol) in anhydrous N,N-dimethyl formamide (
10 ml)
~ o was added triisopropylsilyl chloride ( l45 mg, 0.75 mmol) at 0~C. The
solution was stirred
for 1 h at 20~ C) and then cooled to 0~ C prior to addition of sodium hydride
(60%, 120
mg, 3.0 mmol) was added. After 1 h, allyl bromide (363 mg, 3.0 mmol) was
dropwise added
to the solution. The resulting mixture was stirred for 2 h at 20~ C, and then
5 m1 methanol
and 5 ml ethyl acetate were slowly added at 0~ C. After 30 min the mixture was
extracted
i s with ethyl acetate (3x50 ml). The combined organic layers were washed with
brine, dried
over MgS04, and concentrated to a yellow oil, which was dissolved in MgSOq,
and
concentrated to a yellow oil, which was dissolved in 10 m1 ethanol/2.0 ml 1 N
hydrochloric
acid and refluxed for 5 hrs. The reaction mixture was alkalized with 1 N
aqueous NH40H
solution, extracted with ethyl acetate (3x50 ml). The combined organic layers
were washed
zo with brine) dried over MgSOq., and concentrated to give a crude product,
which was
purified by silica gel column chromatography (Hexane: CHC13 (75:2y50:50)-
~CHCl3:
AcOEt (75:25--Q50:50-~AcOEt)) to afford compound 25 ( 106 mg, 46%) as the free
base
(colorless oil). 1H NMR (CDCl3): 8 7.50-7.08 (m, 4 arom. H), 6.70-6.45 (m, 2
arom. H),
5.75 (m, 1 H, CH=C) 5.65 (s, H-C(5)), 5.18-4.82 (m, 2H), 4.81 (br s, OH), 4.25
and 3.90
2s (m, OCH2).
A solution of this free base in anhydrous ethyl ether (5 ml) was treated with
HCl/ether
solution ( 1M, 1 ml) at 0~ C. Isolation of the precipitate provided the title
compound 25 as a
solid (hydrochloride salt). M.p. 280-290~ C (dec.), IR (HCl salt, KBr) 3642
(m), 2948 (s),
SUBSTITUTE SHEET (RULE 26)


CA 02269910 1999-04-26
WO 98l22467 PCT/SE96/01497 - -
26
1641 (s), l500 (s), 1375 (s), 1315 (s), 996 (s) 920 (s) cm 1. Analysis
calculated for
C29H29N04~ HCI. 1.1 H20: C 68.05, H 6.34, N, 2.74. Found: C 67.94, H 5.95, N
2.S3.
Example 24
s Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-hydroxy-14-
crotyloxy-
6,7,2',3'-benzo[b]foranomorphinan Hydrochloride (compound 26)
To a stirred solution of naltriben methanesulfonate (256 mg, 0.5 mmol) and N,N-

diisopropylethylamine (260 mg, 2.0 mmol) in anhydrous N,N-dimethyl formamide (
10 ml)
io was added triisopropylsilyl chloride (145 mg, 0.75 mmol) at 0~C. The
solution was stirred
for 1 h at 20~ C, and then cooled to 0~ C prior to addition of sodium hydride
{60%, l20
mg, 3.0 mmol} was added. After 1 h, crotyl bromide (405 mg, 3.0 mmol) was
dropwise
added to the solution. The resulting mixture was stirred for 2 h at 20~ C, and
then 5 ml
methanol and 5 m1 ethyl acetate were slowly added at 0~ C. After 30 min the
mixture was
i 5 extracted with ethyl acetate (3x50 ml). The combined organic layers were
washed with
brine, dried over MgS04, and concentrated to a yellow oil, which was dissolved
in 10 m1
ethanol/2 ml 1 N hydrochloric acid and refluxed for 5 hrs. The reaction
mixture was
alkalized with 1 N aqueous NH40H solution, extracted with ethyl acetate (3x50
ml). The
combined organic layers were washed with brine, dried over MgS04, and
concentrated to
2o give a crude product, which was purified by silica gel column
chromatography (Hexane:
CHCl3 (75:25~50:50)~CHC13: AcOEt (75:2y50:50-~AcOEt)) to afford compound 26
(45 mg, 19%) as the free base (colorless oil). 1 H NMR (CDCl3): 8 7.48-7.08
(m, 4 arom.
H), 6.66-6.48 (m, 2 arom. H), 5.62 (s, H-C{5)), 5.40 (m, 2H, CH=CH), 4.20 and
3.82 (m,
OCH2), 1.48 & 1.52 (m, 3H, Me).
A solution of the free base in anhydrous ethyl ether (5 ml) was treated with
HCl/ether
solution (1M, 1 ml) at 0~ C. Isolation of the precipitate provided the title
compound 26 as a
~
solid in form of its hydrochloride salt. Mp. 245-260 C (dec.). IR (Hcl salt,
Kbr): 3642 {m),
3024 (s), l640 (s), l503 (s), 1325 (s), 927 (s) cm 1.
3a
SUBSTITUTE SHEET (RULE 26)

Representative Drawing

Sorry, the representative drawing for patent document number 2269910 was not found.

Administrative Status

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Administrative Status , Maintenance Fee  and Payment History  should be consulted.

Administrative Status

Title Date
Forecasted Issue Date Unavailable
(86) PCT Filing Date 1996-11-19
(87) PCT Publication Date 1998-05-28
(85) National Entry 1999-04-26
Dead Application 2001-11-19

Abandonment History

Abandonment Date Reason Reinstatement Date
2000-11-20 FAILURE TO PAY APPLICATION MAINTENANCE FEE

Payment History

Fee Type Anniversary Year Due Date Amount Paid Paid Date
Registration of a document - section 124 $100.00 1999-04-26
Application Fee $300.00 1999-04-26
Maintenance Fee - Application - New Act 2 1998-11-19 $100.00 1999-04-26
Maintenance Fee - Application - New Act 3 1999-11-19 $100.00 1999-09-16
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
ASTRA AKTIEBOLAG
Past Owners on Record
SCHMIDHAMMER, HELMUT
SCHWARZ, PETER
WEI, ZHONG-YONG
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Description 1999-04-26 26 1,094
Abstract 1999-04-26 1 41
Claims 1999-04-26 8 198
Cover Page 1999-07-19 1 26
Assignment 1999-04-26 3 127
PCT 1999-04-26 13 416
Prosecution-Amendment 1999-04-26 1 18